The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Open accessAbstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune responses are improved by introducing two consecutive proline residues (2P), which are known to retain the full-length S protein in the prefusion conformation.64,65”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both vaccines encode the same full-length, pre-fusion stabilized severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein13,14 and are encapsulated in lipid nanoparticles (LNPs) with identical composition.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stabilizing coronavirus spike proteins by substituting two prolines at the top of heptad repeat 1 prevents structural rearrangements of the fusion (S2) subunit.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, S-2P conformational stability translates into greater immunogenicity,27-29 based on preservation of neutralization-sensitive epitopes at the apex of the prefusion molecule, as shown for respiratory syncytial virus F glycoprotein,30 and improved protein expression,27 which is particularly advantageous for gene-based antigen delivery.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743
Comparative Protein Structure Modeling Using MODELLER
Webb, B., & Šali, A. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.3 · Cited by 4,404
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
Cited by
Sorted by citations
Items 501–600 of 1,000
O’Kennedy, M. M., Abolnik, C., Smith, T., Motlou, T. P., Goosen, K., Sepotokele, K. M., Roth, R., du Preez, I., Truyts, A., Stark, H. C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.050 · Cited by 20
Structural determinants of spike infectivity in bat SARS-like coronaviruses RsSHC014 and WIV1
Qiao, S., & Wang, X. (2024) · Journal of Virology · doi:10.1128/jvi.00342-24 · Cited by 16
Gooch, K. E., Smith, T. R. F., Salguero, F. J., Fotheringham, S. A., Watson, R. J., Dennis, M. J., Handley, A., Humphries, H. E., Longet, S., Tipton, T., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.057 · Cited by 18
BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
Ji, R.-R., Qu, Y., Zhu, H., Yang, Y., Vogel, A. B., Şahin, U., Qin, C., & Hui, A. (2021) · Vaccines · doi:10.3390/vaccines9040324 · Cited by 19
BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2Preprint
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.11.421008 · Cited by 18
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
Kalnin, K. V., Plitnik, T., Kishko, M., Zhang, J., Zhang, D., Beauvais, A., Anosova, N. G., Tibbitts, T., DiNapoli, J. M., Huang, P.-W. D., et al. (2020) · doi:10.1101/2020.10.14.337535 · Cited by 18
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18
Designed miniproteins potently inhibit and protect against MERS-CoV
Ragotte, R. J., Tortorici, M. A., Catanzaro, N., Addetia, A., Coventry, B., Froggatt, H. M., Lee, J., Stewart, C., Brown, J. T., Goreshnik, I., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115760 · Cited by 18
Kacherovsky, N. A., Yang, L. F., Dang, H. V., Cheng, E. L., Cardle, I. I., Walls, A. C., McCallum, M., Sellers, D. L., DiMaio, F., Salipante, S. J., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202107730 · Cited by 18
Protein engineering responses to the COVID-19 pandemic
Hsieh, C., & McLellan, J. S. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102385 · Cited by 17
Self-citationNucleic Acid Vaccines against SARS-CoV-2
Liu, Y., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10111849 · Cited by 17
Wang, J. Y., Khmelinskaia, A., Sheffler, W., Miranda, M. C., Antanasijevic, A., Borst, A. J., Torres, S. V., Shu, C., Hsia, Y., Nattermann, U., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214556120 · Cited by 17
Self-citationIslam, M. M., Khanom, H., Farag, E., Mim, Z. T., Naidoo, P., Mkhize‐Kwitshana, Z. L., Tibbo, M., Islam, A., Magalhães, R. J. S., & Hassan, M. M. (2023) · One Health · doi:10.1016/j.onehlt.2023.100561 · Cited by 18
McConnell, S. A., Sachithanandham, J., Mudrak, N. J., Zhu, X., Farhang, P. A., Cordero, R. J. B., Wear, M. P., Shapiro, J. R., Park, H.-S., Klein, S. L., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.011 · Cited by 17
McCool, R. S., Mukhamedova, M., Bush, S. M., Derrien-Colemyn, A., Acreman, C. M., Wrapp, D., Ruckwardt, T. J., Graham, B. S., Mascola, J. R., & McLellan, J. S. (2023) · Journal of Virology · doi:10.1128/jvi.00929-23 · Cited by 19
Self-citationSARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses
Mo, C., Li, X., Wu, Q., Fan, Y., Liu, D., Zhu, Y., Yang, Y., Liao, X., Zhou, Z., Zhou, L., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.059 · Cited by 18
Towards Innovative Design and Application of Recombinant Eimeria as a Vaccine Vector
Tang, X., Liu, X., & Suo, X. (2020) · Infection and Immunity · doi:10.1128/iai.00861-19 · Cited by 18
Rapid Response Subunit Vaccine Design in the Absence of Structural Information
Wijesundara, D. K., Avumegah, M. S., Lackenby, J. A., Modhiran, N., Isaacs, A., Young, P. R., Watterson, D., & Chappell, K. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592370 · Cited by 18
How Did We Get a COVID-19 Vaccine in Less Than 1 Year?
Wherry, E. J., Jaffee, E. M., Warren, N. J. H., DʼSouza, G., & Ribas, A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0079 · Cited by 18
Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses
Russell, C. J., & Hurwitz, J. L. (2021) · Viruses · doi:10.3390/v13061023 · Cited by 19
Ohtsuka, J., Imai, M., Fukumura, M., Maeda, M., Eguchi, A., Ono, R., Maemura, T., Ito, M., Yamayoshi, S., Kataoka, Y., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103379 · Cited by 20
Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein
Wolf, K., Kwan, J. C., & Kamil, J. P. (2022) · mBio · doi:10.1128/mbio.02030-21 · Cited by 17
Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield
Wrapp, D., Mu, Z., Thakur, B., Janowska, K., Ajayi, O. H., Barr, M., Parks, R., Mansouri, K., Edwards, R. J., Hahn, B. H., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01673-22 · Cited by 18
Self-citationCarrique, L., Duyvesteyn, H. M. E., Malinauskas, T., Zhao, Y., Ren, J., Zhou, D., Walter, T. S., Radecke, J., Huo, J., Ruza, R. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.13.249177 · Cited by 18
An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies
Zhang, N., Shang, J., Li, C., Zhou, K., & Du, L. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1813574 · Cited by 18
SARS-CoV-2 virus: Vaccines in development
Huang, Q., & Yan, J. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.009 · Cited by 18
Accelerating clinical trial development in vaccinology: COVID-19 and beyond
Corey, L., & Miner, M. D. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102206 · Cited by 17
Khare, S., Niharika, N., Singh, A., Hussain, I., Singh, N. B., & Singh, S. C. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04181-3 · Cited by 16
Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes
Zhang, X., Li, Z., Zhang, Y., Liu, Y., Wang, J., Liu, B., Chen, Q., Wang, Q., Fu, L., Wang, P., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201796 · Cited by 16
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
McNamara, R. P., Maron, J. S., Boucau, J., Roy, V., Webb, N. E., Bertera, H. L., Barczak, A. K., Staff, T., Franko, N., Logue, J. K., et al. (2023) · mBio · doi:10.1128/mbio.00902-23 · Cited by 17
Self-citationLangedijk, J. P. M., Cox, F., Johnson, N. V., van Overveld, D., Le, L., van den Hoogen, W., Voorzaat, R., Zahn, R. C., van der Fits, L., Juraszek, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48059-w · Cited by 17
Self-citationProtein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18
An effective drug against COVID-19: reality or dream?
Yaghoubi, A., Jamehdar, S. A., Movaqar, A., Milani, N., & Soleimanpour, S. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1854092 · Cited by 17
Goodsell, D. S., & Burley, S. K. (2021) · Structure · doi:10.1016/j.str.2021.10.008 · Cited by 17
Struble, L. R., Smith, A. L., Lutz, W. E., Grubbs, G., Sagar, S., Bayles, K. W., Radhakrishnan, P., Khurana, S., El‐Gamal, D., & Borgstahl, G. E. O. (2022) · Protein Science · doi:10.1002/pro.4300 · Cited by 16
Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states
Zhou, M., Vollmer, B., Machala, E. A., Chen, M., Grünewald, K., Arvin, A. M., Chiu, W., & Oliver, S. L. (2023) · Nature Communications · doi:10.1038/s41467-023-43011-w · Cited by 16
Molecular medical microbiology—from bench to bedside
Tang, Y., Hindiyeh, M. Y., Liu, D., Sails, A. D., Spearman, P. W., & Zhang, J.-R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00027-7 · Cited by 18
Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity
Rutten, L., Swart, M., Koornneef, A., Bouchier, P., Blokland, S., Sadi, A., Juraszek, J., Vijayan, A., Schmit-Tillemans, S. P. R., Verspuij, J. W. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56293-x · Cited by 18
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
Roederer, A. L., Cao, Y., Denis, K. S., Sheehan, M. L., Li, C. J., Lam, E. C., Gregory, D. J., Poznansky, M. C., Iafrate, A. J., Canaday, D. H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101850 · Cited by 18
Gniffke, E. P., Harrington, W. E., Dambrauskas, N., Jiang, Y., Trakhimets, O., Vigdorovich, V. I., Frenkel, L. M., Sather, D. N., & Smith, S. E. P. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa508 · Cited by 17
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein
Choi, J., Goo, J., Yang, E., Jung, D., Lee, S., Rho, S., Jeong, Y., Park, Y.-S., Park, H., Moon, Y.-H., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01176-20 · Cited by 16
Andryukov, B. G., Besednova, N. N., Kuznetsova, T. A., & Fedyanina, L. N. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11010042 · Cited by 16
Gu, M., Torres, J. L., Li, Y., Ry, A. V., Greenhouse, J. J., Wallace, S. M., Chiang, C.-I., Pessaint, L., Jackson, A. M., Porto, M., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1994354 · Cited by 16
Self-citationMargolin, E., Verbeek, M., de Moor, W. R. J., Chapman, R., Meyers, A., Schäfer, G., Williamson, A., & Rybicki, E. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2021.798822 · Cited by 15
Satta, S., Shahabipour, F., Gao, W. F., Lentz, S. R., Perlman, S. M., Ashammakhi, N. A., & Hsiai, T. K. (2022) · Theranostics · doi:10.7150/thno.72339 · Cited by 16
Grant, O. C. (2021) · ModelArchive SIB · doi:10.5452/ma-zykoq · Cited by 16
Zhang, S., Qiao, S., Yu, J., Zeng, J., Shan, S., Lan, J., Tian, L., Zhang, L., & Wang, X. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.21.307439 · Cited by 16
Aditham, A. K., Radford, C. E., Carr, C. R., Jasti, N., King, N. P., & Bloom, J. D. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.018 · Cited by 15
D’Arco, A., Fabrizio, M. D., Mancini, T., Mosetti, R., Macis, S., Tranfo, G., Ventura, G. D., Marcelli, A., Petrarca, M., & Lupi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119550 · Cited by 15
RNA vaccines: A transformational advance
Brown, B. D., Fauci, A. S., Belkaid, Y., & Mérad, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.009 · Cited by 15
Singh, G., Abbad, A., Kleiner, G., Srivastava, K., Gleason, C., PARIS Study Group, Carreño, J. M., Simon, V. R., Krammer, F., Andre, D., et al. (2023) · mBio · doi:10.1128/mbio.02250-23 · Cited by 17
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 15
Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time?
Krammer, F. (2020) · Med · doi:10.1016/j.medj.2020.11.004 · Cited by 15
Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
Song, D., Wang, W., Dong, C., Ning, Z., Liu, X., Liu, C., Du, G., Sha, C., Wang, K., Lu, J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02029-w · Cited by 15
Self-citationSARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity
Olia, A. S., Tsybovsky, Y., Chen, S. J., Liu, C., Nazzari, A. F., Ou, L., Wang, L., Kong, W., Leung, K., Liu, T. W. B., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101127 · Cited by 14
Self-citationImmunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Imaging and visualizing SARS-CoV-2 in a new era for structural biology
Leigh, K. E., & Modis, Y. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0019 · Cited by 17
Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints
Eldrid, C., Allen, J. D., Newby, M. L., & Crispin, M. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01772 · Cited by 15
Leonard, A. C., Weinstein, J. J., Steiner, P. J., Erbse, A. H., Fleishman, S. J., & Whitehead, T. A. (2022) · Protein Engineering Design and Selection · doi:10.1093/protein/gzac002 · Cited by 15
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity
Liao, H., Wu, W.-L., Chiang, C.-Y., Huang, M., Shen, K., Huang, Y., Wu, S., Liao, C., Chen, H., & Liu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094902 · Cited by 15
Qiao, S., Zhang, S., Ge, J., & Wang, X. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13454 · Cited by 16
Cryo-EM as a powerful tool for drug discovery: recent structural based studies of SARS-CoV-2
Kim, H., & Jung, H. S. (2021) · Han-guk hyeonmigyeong hakoeji/Applied microscopy · doi:10.1186/s42649-021-00062-x · Cited by 14
Choi, J.-A., & Kim, J. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1547-8 · Cited by 15
Tee, K. L., Jackson, P. J., Scarrott, J. M., Jaffe, S., Johnson, A. O., Johari, Y. B., Pohle, T. H., Mozzanino, T., Price, J., Grinham, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.231282 · Cited by 14
Dipeptidase 1 is a functional receptor for a porcine coronavirus
Dufloo, J., Fernández, I., Arbabian, A., Haouz, A., Temperton, N. J., Gimenez-Lirola, L. G., Rey, F. A., & Sanjuán, R. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02111-7 · Cited by 13
Viral informatics: bioinformatics-based solution for managing viral infections
Kumar, S., Kumar, G. S., Maitra, S. S., Malý, P., Bharadwaj, S., Sharma, P., & Dwivedi, V. D. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac326 · Cited by 15
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice
Walls, A. C., VanBlargan, L. A., Wu, K., Choi, A., Navarro, M. J., Lee, D. W., Avena, L. E., Berrueta, D. M., Pham, M. N., Elbashir, S. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111299 · Cited by 13
Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection
Wang, R., Han, Y., Zhang, R., Zhu, J., Nan, X., Liu, Y., Yang, Z., Zhou, B., Yu, J., Lin, Z., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.10.007 · Cited by 13
Interrogating ligand-receptor interactions using highly sensitive cellular biosensors
Funk, M. A., Leitner, J. M., Gerner, M. C., Hammerler, J. M., Salzer, B., Lehner, M., Battin, C., Gumpelmair, S., Stiasny, K., Grabmeier‐Pfistershammer, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43589-1 · Cited by 14
Wang, Y., Song, J., Wang, J., Wang, J., Zhang, M., Liu, Y., Tang, P., Liu, H., Zhou, Y., Tong, G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328266 · Cited by 14
Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses
Olmedillas, E., Cano, O., Martínez, I., Luque, D., Terrón, M. C., McLellan, J. S., Melero, J. A., & Más, V. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708078 · Cited by 14
Self-citationA high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry
Rosen, O., Chan, L. L.-Y., Abiona, O. M., Gough, P., Wang, L., Shi, W., Zhang, Y., Wang, N., Kong, W., McLellan, J. S., et al. (2018) · Journal of Virological Methods · doi:10.1016/j.jviromet.2018.11.009 · Cited by 14
Self-citationChun, J., Cho, Y., Park, K. H., Choi, H., Cho, H., Lee, H. J., Jang, H. G., Kim, K. H., Oh, Y., & Kim, Y. B. (2019) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1903.03043 · Cited by 14
Tian, H., & Tao, P. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1802338 · Cited by 15
Shi, Y., Shi, J., Sun, L., Tan, Y., Wang, G., Guo, F., Hu, G., Fu, Y., Fu, Z. F., Xiao, S., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02284-20 · Cited by 14
Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2
Choudhary, V., Gupta, A., Sharma, R., & Parmar, H. S. (2021) · Journal of Proteins and Proteomics · doi:10.1007/s42485-021-00074-x · Cited by 15
Rosati, M., Agarwal, M., Hu, X., Devasundaram, S., Stellas, D., Chowdhury, B., Bear, J., Burns, R., Donohue, D. E., Pessaint, L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009701 · Cited by 14
Alimohammadi, R., Porgoo, M., Eftekhary, M., Kiaie, S. H., Dezfouli, E. A., Dehghani, M., Nasrollahi, K., Malekshahabi, T., Heidari, M., Pouya, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00528-3 · Cited by 13
Ruigrok, K., Vaney, M. C., Buchrieser, J., Baquero, E., Hellert, J., Baron, B., England, P., Schwartz, O., Rey, F. A., & Backović, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.10.020 · Cited by 14
Targeting Viral Surface Proteins through Structure-Based Design
Narkhede, Y. B., Gonzalez, K. J., & Strauch, E. (2021) · Viruses · doi:10.3390/v13071320 · Cited by 15
Leddy, O. K., Ogongo, P., Huffaker, J., Gan, M., Milligan, R., Mahmud, S., Ni, H. M., Yuki, Y., Bobosha, K., Wassie, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adw9184 · Cited by 16
Immune thrombocytopenia purpura flare post COVID-19 vaccine
Ali, E., Al-maharmeh, Q., Rozi, W., Habib, M. B., Abdallah, A., Abdulgayoom, M., & Yassin, M. A. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.103164 · Cited by 13
Renner, T. M., Akache, B., Stuible, M., Rohani, N., Donates, Y. C., Deschatelets, L., Dudani, R., Harrison, B. A., Baardsnes, J., Koyuturk, I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182556 · Cited by 13
Sepotokele, K. M., O’Kennedy, M. M., Wandrag, D. B. R., & Abolnik, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288970 · Cited by 13
McCraw, D. M., Myers, M. L., Gulati, N. M., Prabhakaran, M. S., Brand, J., Andrews, S. F., Gallagher, J. R., Maldonado-Puga, S., Kim, A. J., Torian, U., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011514 · Cited by 13
Wang, J., Ma, Y., Li, Z., Yuan, H., Liu, B., Li, Z., Su, M., Habib, G., Liu, Y., Fu, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr8772 · Cited by 14
Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection
Saha, P., Fernandez, I., Sumbul, F., Valotteau, C., Kostrz, D. N., Meola, A., Baquero, E., Sharma, A., Portman, J. R., Stransky, F., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01908-1 · Cited by 14
The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis
Silva, D. S. D. O. D. E., & da Fonseca, F. G. (2021) · Vaccines · doi:10.3390/vaccines9101101 · Cited by 13
Nyagwange, J., Kutima, B., Mwai, K., Karanja, H., Gitonga, J. N., Mugo, D., Sein, Y., Wright, D., Omuoyo, D. O., Nyiro, J. U., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.041 · Cited by 10
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
Marzi, R., Bassi, J., Silacci-Fregni, C., Bartha, I., Muoio, F., Culap, K., Sprugasci, N., Lombardo, G., Saliba, C., Cameroni, E., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105726 · Cited by 12
Capone, S., Fusco, F. M., Milleri, S., Borrè, S., Carbonara, S., Caputo, S. L., Leone, S., Gori, G., Maggi, P., Cascio, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101084 · Cited by 13
Choi, J.-H., Woo, H., Lee, T.-Y., Lee, S. Y., Shim, S., Park, W.-J., Yang, J., Kim, J. A., Yun, M., Kim, D.-W., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232757 · Cited by 13
Self-citationAnalysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine candidatePreprint
Brun, J., Vasiljević, S., Gangadharan, B., Hensen, M., Chandran, A. V., Hill, M. L., Kiappes, J. L., Dwek, R. A., Alonzi, D. S., Struwe, W. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.16.384594 · Cited by 13
Would It Be Possible to Stabilize Prefusion SARS-COV-2 Spikes with Ligands?Preprint
Lorenzo, M. M., Blasco, R., & Coll, J. M. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13453919.v2 · Cited by 17
Cell-Free Expression of Nipah Virus Transmembrane Proteins for Proteoliposome Vaccine Design
Hu, V. T., Ezzatpour, S., Selivanovitch, E., Sahler, J., Pal, S., Carter, J., Pham, Q. V., Adeleke, R. A., August, A., Aguilar, H. C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16190 · Cited by 13
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
Radić, L., Sliepen, K., Yin, V. C., Brinkkemper, M., Capella-Pujol, J., Schriek, A. I., Torres, J. L., Bangaru, S., Burger, J. A., Poniman, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106540 · Cited by 12
Self-citationViral Prototypes for Pandemic Preparedness: The Road Ahead
Morabito, K. M., Cassetti, M. C., DeRocco, A. J., Deschamps, A. M., & Pierson, T. C. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad267 · Cited by 14
Montoya, B., Melo‐Silva, C. R., Tang, L., Kafle, S., Lidskiy, P., Bajusz, C., Vadovics, M., Muramatsu, H., Ábrahám, E., Lipinszki, Z., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.019 · Cited by 14
Molecular basis of host recognition of human coronavirus 229E
Tsai, Y.-X., Chien, Y.-C., Hsu, M., Khoo, K., & Hsu, S. D. (2025) · Nature Communications · doi:10.1038/s41467-025-57359-8 · Cited by 13
Metadata
- Authors
- Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & McLellan, J. S.
- Affiliations
- Scripps Research Institute (US)
- Dartmouth College (US)
- National Institute of Allergy and Infectious Diseases (US)
- Vanderbilt University Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Pallesen, Jesper
- Wang, Nianshuang
- Corbett, Kizzmekia S.
- Ward, Andrew B.
- McLellan, Jason S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-08-14
- Volume
- 114
- Issue
- 35
- Pages
- E7348-E7357
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5584442
- OpenAlex
- W2750464792
- Cited by
- 1,073
- References
- 89
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 98 · 2023: 127 · 2022: 174 · 2021: 275 · 2020: 220 · 2019: 31 · 2018: 17 · 2017: 6
- FWCI
- 57.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI127521)
- HHS | NIH | National Institute of General Medical Sciences (P20GM113132)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI005125)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- MERS-CoV, spike protein, structure-based vaccine design, neutralizing antibodies, receptor binding domain, receptor recognition, membrane fusion mechanism, coronavirus vaccines
- MeSH terms
- Animals, Antibodies, Viral, Coronaviridae, Humans, Immunoglobulin G, Mice, Inbred BALB C, Protein Binding, Protein Conformation, Receptors, Virus, Structure-Activity Relationship, Vaccination, Viral Vaccines, Coronavirus Infections, Crystallography, X-Ray, Immunity, Humoral, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
